US Home Infusion Therapy Market

US Home Infusion Therapy Market Executive Summary

The US Home Infusion Therapy market is at around $15103.2 Mn in 2023 and is projected to reach $22860 Mn in 2030, exhibiting a CAGR of 6.1% during the forecast period.

Home infusion involves the administration of a medication through a needle or catheter at a patient’s home instead of a hospital or other medical facility. For individuals requiring long-term therapy, inpatient care is not only tremendously expensive but also prevents the individual from resuming normal lifestyle and work activities. Home infusion is a safe and effective alternative to inpatient care for a variety of therapies and disease states, both acute and chronic. Conditions commonly requiring infusion therapy include infections that are unresponsive to oral antibiotics, cancer and cancer-related pain, dehydration, gastrointestinal diseases or disorders which prevent normal functioning of the gastrointestinal system, immune system diseases (Crohn’s Disease, rheumatoid arthritis, multiple sclerosis) and more. Some infusion treatments require infusions every day, while others may be less frequent such as every few weeks or months. Usually, for the majority of patients and drugs, home infusion is safe. However, home infusion clinicians will evaluate a patient’s suitability for home infusion throughout the intake phase. The evaluation aspects include the safety of the home environment, safety of the medication delivery method, capability to learn and self-manage for patients and/or caregivers, and the capability to store medications. Thus, nurses play a crucial role in home infusion therapy as they train patients and caregivers on how to safely administer the medication, monitor for side effects, and provide ongoing support. Moreover, coordination between a number of parties is usually necessary for the home infusion procedure, including patients, doctors, hospital discharge planners, health plans, home infusion pharmacies, and, home health organizations.

The US faces a heavy burden in the healthcare sector due to the rising chronic diseases prevalence as approximately 129 Mn of the total 330 Mn population are suffering from at least one chronic disease. The US Home Infusion Therapy Market is driven by significant factors such as the rising prevalence of chronic diseases, expanding geriatric population, and technological advancements. However, uncertain reimbursement policies, limited availability of nurses, and infrastructure and accessibility issues restrict the growth and potential of the market.

The major players of the US Home Infusion Therapy Market are Option Care Health, Baxter International, ICU Medical (Smiths Medical), Becton, Dickinson and Company (BD), and Fresenius Kabi, among others.

Market Dynamics

Market Growth Drivers

Rising Prevalence of Chronic Diseases: The overall national prevalence of any chronic disease among adults in US is increasing. According to the Centre for Disease Control and Prevention (CDC), approximately 129 Mn have at least one major chronic disease including diabetes, cancer, and hypertension. Home infusion is a safe and effective method to manage these chronic conditions as it is convenient which leads to improved patient adherence and treatment outcomes. For example, chemotherapy medications can be safely given to cancer patients at home, which lowers hospital stays and enhances patient comfort while receiving treatment. For patients with extensive diabetes care needs, insulin or other drugs can also be administered at home by infusion. Consequently, there is an increasing need for novel and efficient treatment approaches due to the increased prevalence of chronic illnesses. Because of its affordability, flexibility to different chronic conditions, and ease of use, home infusion therapy is becoming more and more popular as a means of managing chronic illnesses and enhancing patient quality of life, which is driving the market’s overall expansion.

Expanding Geriatric Population: The number of Americans aged 65 and older is projected to increase from 58 Mn in 2022 to 82 Mn by 2050 which is an increase of 47% and this group’s share of the total population will increase from 17% to 23%. As people age, they get more prone to long-term illnesses including diabetes, heart failure, and autoimmune disorders as they age. Many times, these illnesses necessitate long-term care using drugs that may be efficiently administered at home via infusion therapy. Moreover, the aging population is marked by a decline in mobility, which makes regular hospital visits difficult. A practical substitute is home infusion therapy, which enables patients to receive treatment in the comfort of their own homes, enhancing their quality of life and lessening the strain on caregivers. Furthermore, hospital environments can raise the risk of infection for older persons, who are more vulnerable to illnesses. However, home infusion therapy can improve patient outcomes by lowering the chance of contracting infections acquired outside of a hospital. The market for home infusion therapy is ultimately driven by the number of potential patients who may need it to manage chronic diseases, which is generally increased with the aging population.

Market Restraints

Technological advancements: The home infusion therapy market is expected to grow at a high rate due to the numerous advantages that technological advancements provide. Patients can move around more freely and independently while receiving therapy because of the smaller, lighter, and more user-friendly designs of more recent portable pump models. In order to improve safety and convenience, real-time data transfer from infusion pumps to healthcare providers allows for remote monitoring of medicine distribution and patient vitals. Automated dose calculations, preprogrammed reminders, and malfunction alarms are just a few of the features that smart infusion pumps provide to increase medication accuracy and lower error rates. These technical developments result in better patient acceptance, a wider range of treatments, greater efficiency for medical professionals, and lower costs, all of which raise demand and fuel the market for home infusion therapy.

Uncertain Reimbursement Policies: The varied and unclear reimbursement policies from private insurance companies and the government can limit patient access to home infusion therapy. Even though, home infusion therapy is much more affordable to patients rather than receiving in-patient care, there can be high costs associated with certain speciality infusion therapies. These high costs associated with specialty infusion treatment may discourage patients, especially those without adequate insurance coverage. Due to this, the Home Infusion Therapy Market gets affected as it faces resistance from the patients.

Limited Availability of Nurses: One of the major challenges of home infusion therapy is the shortage of trained nurses which results in fewer people being able to receive care at home and lengthier wait times. Prolonged wait times eventually prevents patients from using home infusion therapy and choose an alternative treatment. To attract and retain qualified healthcare professions, providers of home infusion therapy may need to offer higher salaries. This increases the operating expenses, which leads to overall high cost of the treatment, further restricting the market access. Thus, the market for home infusion therapy is constrained by a lack of competent workers which ultimately slows the market growth.

Infrastructure and Accessibility Issues: In isolated or rural places, the availability of home infusion therapy services may be restricted. Patients who do not have access to qualified clinicians and necessary equipment for the home infusion therapy suffer. Additionally, the growth of home infusion therapy in some areas may not have sufficient cold chain logistics for the storage and transportation of temperature-sensitive drugs. As a result, this impacts the expansion of the home infusion therapy market as a whole.

Regulatory Landscape and Reimbursement Scenario

The United States Food and Drug Administration (USFDA) is a federal agency of the Department of Health and Human Services. The main goal of the USFDA is to protect public health by ensuring the safety and efficacy of drugs, biological products, medical equipment, along with food, cosmetics, and items that emit radiations. The Federal Food, Drug, and Cosmetic Act and several other comparable statutes are enforced by the FDA.

The process of gaining approval of new drugs involve rigorous and cumbersome evaluation by the USFDA. The two divisions of the USFDA, Centre for Drug Evaluation and Research (CDER) and the Centre for Biologics Evaluation and Research (CBER) extensively review applications for approval which makes it challenging for pharmaceutical companies to bring a new product to the market. The various types of applications submitted to the USFDA for getting approval of pharmaceuticals include Investigational New Drug Application (INDA), New Drug Application (NDA), Abbreviated New Drug Application (ANDA) for generic drugs and Biologics License Application (BLA).

Medicare and Medicaid are two of the health insurance programs administered by the US Government, with differences in covered services and cost-sharing. Medicare is a government health insurance program available to Americans 65 years of age or older, as well as to younger individuals with disabilities. Medicaid provides health coverage to low-income families, based on eligibility determined by comparing the income with the federal poverty level. Initially launched in 1965 by the Social Security Administration, the Centres for Medicare and Medicaid Services (CMS) currently oversee its administration. Medicare and Medicaid thus provide financial security and lessen the financial burden of healthcare and provides better outcomes for beneficiaries.

Competitive Landscape

Key Players

Here are some of the major key players in the US Home Infusion Therapy Market:

• Option Care Health
• Baxter International
• ICU Medical (Smiths Medical)
• Becton, Dickinson and Company (BD)
• Fresenius Kabi
• Paragon Healthcare
• Medtronic
• B. Braun Melsungen AG
• Terumo Corporation
• CareFusion Corporation